Feedback from a point-of-care test for nicotine intake to reduce smoking during pregnancy.

What Was Tested

Researchers studied Therapeutic nicotine (patch, non-peptide) in this randomized controlled trial publication.

Smoking is the most important modifiable risk factor for adverse pregnancy outcome in the UK.

Who Took Part

According to the abstract, 856 women were involved.

PubMed tags the participants as women only.

A cross-sectional randomized controlled trial involving 856 pregnant women.

All intervention patients were interviewed at their initial visit and tested for smoking.

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The test provided visual and numerical feedback.

Smokers were followed up and retested at subsequent visits.

The control group received anti-smoking counselling as part of routine care, but their smoking was monitored using the test.

Both groups were interviewed and retested at 36 weeks' gestation.

What Was Measured

Smoking is the most important modifiable risk factor for adverse pregnancy outcome in the UK.

PubMed files the paper under topics including Counseling, Nicotine, Patient Education as Topic, Point-of-Care Systems, Pregnancy Outcome, Pregnant People and Prenatal Care.

What This Means in Plain Language

The paper is a randomized study of Therapeutic nicotine (patch, non-peptide) in 856 women.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2003 (Annals of clinical biochemistry), a journal based in England.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.